Collaboration to Study Merck KGaA/Pfizer’s Avelumab with Verastem’s VS-6063

Combination therapy will be subject of Phase I/Ib study set to start in the second half of this year

Advanced Immunotherapeutic Method Shows Promise against Brain Cancer

Researchers develop novel technique to induce a specific type of cell death in brain cancer cells from mice

AstraZeneca to Sell Moventig’s European Rights to ProStrakan

$70 million deal covers the E.U, as well as Iceland, Norway, Switzerland and Liechtenstein.

Chimerix Axes 20% of Workforce, Citing Phase III Failure

Company eliminates 26 jobs, leaving it with 105 employees, after lead product Brincidofovir misses primary endpoint

Ipsen Partnering with Exelixis to Develop Cabozantinib

Collaboration could generate up to $855M-plus for Exelixis, two years after the failure of a Phase III trial of the treatment in prostate cancer

First Human Vaccine Trial for Most Widespread Species of Malaria

Researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

Genetically Engineered E. coli Cranks Out Opiate Precursor

Bacteria engineered in Japan yield 300 times more opiates than yeast

UCB Terminates Epratuzumab Collaboration with Immunomedics

Termination follows the disclosure in July that epratuzumab failed two Phase III trials in systemic lupus erythematosus

Juno, Fred Hutch Launch Clinical Trials Unit

Seattle Cancer Care Alliance, University of Washington join immunotherapy developer, research institute in creating center focused on consolidating care, research

Understanding GMP Reagents and Their Role in Cell Therapy Broadcast Date: February 23rd, 2016Time: 11:00 am ET, 8:00 am PT The use of human cells as therapeutic interventions is a revolution for biomedical science. Cell therapies...